These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38795120)

  • 1. End of induction [
    Guerra L; Chauvie S; Fallanca F; Bergesio F; Marcheselli L; Durmo R; Peano S; Franceschetto A; Monaco L; Barbieri E; Ladetto M; Musuraca G; Tosi P; Bianchi B; Bolis SAM; Pavone V; Chiarenza A; Arcari A; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Roti G; Galimberti S; Gini G; Falcinelli F; Vitolo U; Usai SV; Stefani PM; Ibatici A; Liberati AM; Pennese E; Perrone T; Versari A; Luminari S;
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3311-3321. PubMed ID: 38795120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
    Kobe C; Goergen H; Baues C; Kuhnert G; Voltin CA; Zijlstra J; Hoekstra O; Mettler J; Drzezga A; Engert A; Borchmann P; Dietlein M
    Blood; 2018 Nov; 132(21):2273-2279. PubMed ID: 30166329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
    Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
    J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
    Luminari S; Manni M; Galimberti S; Versari A; Tucci A; Boccomini C; Farina L; Olivieri J; Marcheselli L; Guerra L; Ferrero S; Arcaini L; Cavallo F; Kovalchuk S; Skrypets T; Del Giudice I; Chauvie S; Patti C; Stelitano C; Ricci F; Pinto A; Margiotta Casaluci G; Zilioli VR; Merli A; Ladetto M; Bolis S; Pavone V; Chiarenza A; Arcari A; Anastasia A; Dondi A; Mannina D; Federico M;
    J Clin Oncol; 2022 Mar; 40(7):729-739. PubMed ID: 34709880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.
    Trotman J; Luminari S; Boussetta S; Versari A; Dupuis J; Tychyj C; Marcheselli L; Berriolo-Riedinger A; Franceschetto A; Julian A; Ricard F; Guerra L; Haioun C; Biasoli I; Tilly H; Federico M; Salles G; Meignan M
    Lancet Haematol; 2014 Oct; 1(1):e17-27. PubMed ID: 27030064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
    Ceriani L; Martelli M; Gospodarowicz MK; Ricardi U; Ferreri AJ; Chiappella A; Stelitano C; Balzarotti M; Cabrera ME; Cunningham D; Guarini A; Zinzani PL; Giovanella L; Johnson PW; Zucca E
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):42-49. PubMed ID: 27839910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
    Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
    Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
    Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
    Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Dixon JG; Dimier N; Nielsen T; Zheng J; Marcus R; Morschhauser F; Evens AM; Federico M; Blum KA; Shi Q
    Br J Haematol; 2022 Jul; 198(2):333-337. PubMed ID: 35491747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
    Dai N; Liu H; Deng S; Sang S; Wu Y
    Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
    [No Abstract]   [Full Text] [Related]  

  • 16. FDG PET/CT predictive role in follicular lymphoma.
    Lopci E; Zanoni L; Chiti A; Fonti C; Santi I; Zinzani PL; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):864-71. PubMed ID: 22354449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
    Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
    Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
    Adams HJA; Nievelstein RAJ; Kwee TC
    Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
    Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
    Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.